{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:13:29Z","timestamp":1761912809116,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.therap.2025.04.001","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:29:55Z","timestamp":1744284595000},"page":"619-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous rituximab in indolent primary cutaneous B cell lymphoma: A case series of 5 patients with the evaluation of the medico economic impact"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2209-7760","authenticated-orcid":false,"given":"Carla","family":"Fassanaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e8s","family":"Arib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Dervaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Faiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2025.04.001_bib0045","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.therap.2025.04.001_bib0050","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.therap.2025.04.001_bib0055","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.therap.2025.04.001_bib0060","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)","volume":"28","author":"Rummel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.therap.2025.04.001_bib0065","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/PPA.S108489","article-title":"Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab","volume":"10","author":"Theodore-Oklota","year":"2016","journal-title":"Patient Prefer Adherence"},{"year":"2023","series-title":"NCCN 2023 guidelines: primary cutaneous lymphoma version 1","author":"Horwitz","key":"10.1016\/j.therap.2025.04.001_bib0070"},{"key":"10.1016\/j.therap.2025.04.001_bib0075","first-page":"4676","article-title":"Home administration of subcutaneous rituximab is safe and associated with significant cost saving: a single center experience","volume":"130","author":"Wolfromm","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.therap.2025.04.001_bib0080","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjd.20493","article-title":"Subcutaneous rituximab for autoimmune bullous diseases","volume":"185","author":"Riquelme-Mc Loughlin","year":"2021","journal-title":"Br J Dermatol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725000599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725000599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:07:58Z","timestamp":1761912478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595725000599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0040595725000599"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2025.04.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous rituximab in indolent primary cutaneous B cell lymphoma: A case series of 5 patients with the evaluation of the medico economic impact","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2025.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}